Portola Pharmaceuticals, Inc. Announces Enrollment Has Begun in Phase 1/2 Study of PRT2070, an Oral Dual Syk/JAK Inhibitor for Genetically-Defined Hematologic Cancers

Published: Oct 25, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that patient enrollment has begun in its PRT2070 Phase 1/2 proof-of-concept clinical study. PRT2070 is a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor being developed as a treatment for hematologic cancers, including for those patients who have progressive or relapsed disease, genetically-defined subtypes or acquired mutations.

Help employers find you! Check out all the jobs and post your resume.

Back to news